Shorter drug course after kidney transplant may reduce side effects
NCT ID NCT06374095
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 37 times
Summary
This study looks at 75 kidney transplant patients to compare two different drug plans that help prevent organ rejection. One group gets a single dose of a drug called RATG, while the other gets seven doses over a week. The goal is to see which plan causes fewer side effects like low blood cell counts, while still protecting the new kidney. All patients also receive standard anti-rejection medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY REPLACEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, 24127, Italy
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.